Physicians/Specialists
Facilities/Hospitals
Publication Date: 
2022-02-23

Please note, this communication applies to Healthy Blue + MedicareSM (HMO D-SNP) offered by Blue Cross and Blue Shield of North Carolina (Blue Cross NC).

The Medical Policies, Clinical Utilization Management (UM) Guidelines, and Third-Party Criteria below were developed and/or revised to support clinical coding edits. Note, several policies and guidelines were revised to provide clarification only and are not included. Existing precertification requirements have not changed.

Please share this notice with other members of your practice and office staff.

To view a guideline, visit https://medpol.providers.amerigroup.com/green-provider/medical-policies-and-clinical-guidelines.

Notes/Updates
Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive:

  • *CG-LAB-19 — Laboratory Evaluation of Vitamin B12
    • Outlines the medically necessary and not medically necessary criteria for the use of vitamin B12 blood test.
  • *DME.00044 — Wheelchair Mounted Robotic Arm
    • The use of a wheelchair mounted robotic arm is considered investigational and not medically necessary for all uses.
  • *MED.00138 — Wearable Devices for Stress Relief and Management
    • Wearable devices for management, monitoring or prevention of stress and stress-related conditions are considered investigational and not medically necessary for all indications.
  • *CG-MED-53 — Cervical Cancer Screening Using Cytology and Human Papillomavirus Testing
    • Removed criteria addressing chronically immunosuppressed individuals.
  • *CG-MED-81 — Ultrasound Ablation for Oncologic Indications
    • Added not medically necessary statement for TULSA
  • *CG-SURG-78 — Locoregional and Surgical Techniques for Treating Primary and Metastatic Liver Malignancies
    • Revised the clinical indications to add a not medically necessary statement for histotripsy.
  • *MED.00099 — Navigational Bronchoscopy
    • Removed the word electromagnetic in the position statement.
  • *SURG.00010 — Treatments for Urinary Incontinence
    • Added new criterion to investigational and not medically necessary statement on endovaginal cryogen-cooled, monopolar radiofrequency remodeling.
    • Added as treatments for urinary incontinence to investigational and not medically necessary statement and removed wording on urinary incontinence.
  • *SURG.00097 — Scoliosis Surgery
    • Added minimally invasive deformity correction system to the Scope and Position Statement

Effective May 18, 2022, Blue Cross NC will begin using the AIM Specialty Health®1 Clinical Appropriateness Guidelines for medical necessity review of the below services. Please note, the Healthy Blue + Medicare Utilization Management team will complete these reviews using the AIM Clinical Appropriateness Guidelines:

  • Advanced Imaging Clinical Appropriateness Guideline:
    • Imaging of the brain
    • Imaging of the head and neck
    • Imaging of the heart
    • Imaging of the chest
    • Imaging of the abdomen and pelvis
    • Oncologic imaging
  • Musculoskeletal Interventional Pain Management Clinical Appropriateness Guideline
  • Cardiology Clinical Appropriateness Guidelines:
    • Diagnostic coronary angiography
    • Percutaneous coronary intervention
  • Radiation Oncology Clinical Appropriateness Guideline

Medical Policies
On November 11, 2021, the Medical Policy and Technology Assessment Committee (MPTAC) approved the following Medical Policies applicable to Blue Cross NC. These guidelines take effect May 18, 2022.

Publish Date Medical Policy Number Medical Policy Title New or Revised
12/29/2021 *DME.00044 Wheelchair Mounted Robotic Arm New
12/29/2021 *MED.00138 Wearable Devices for Stress Relief and Management New
11/18/2021 GENE.00052 Whole Genome Sequencing, Whole Exome Sequencing, Gene Panels, and Molecular Profiling Revised
12/29/2021 *MED.00099 Navigational Bronchoscopy Revised
12/29/2021 *SURG.00010 Treatments for Urinary Incontinence Revised
12/29/2021 SURG.00011 Allogeneic, Xenographic, Synthetic, Bioengineered, and Composite Products for Wound Healing and Soft Tissue Grafting Revised
11/18/2021 SURG.00026 Deep Brain, Cortical, and Cerebellar Stimulation Revised
12/29/2021 SURG.00037 Treatment of Varicose Veins (Lower Extremities) Revised
12/29/2021 *SURG.00097 Scoliosis Surgery Revised

Clinical UM Guidelines
On November 11, 2021, the MPTAC approved the following Clinical UM Guidelines applicable to Blue Cross NC. These guidelines were adopted by the medical operations committee for Healthy Blue + Medicare members on December 16, 2021. These guidelines take effect
May 18, 2022.

Publish Date Medical Policy Number Medical Policy Title New or Revised
12/29/2021 *CG-LAB-19 Laboratory Evaluation of Vitamin B12 New
12/29/2021 CG-DME-06 Compression Devices for Lymphedema Revised
12/29/2021 *CG-MED-53 Cervical Cancer Screening Using Cytology and Human Papillomavirus Testing Revised
12/29/2021 *CG-MED-81 Ultrasound Ablation for Oncologic Indications Revised
11/28/2021 CG-OR-PR-05 Myoelectric Upper Extremity Prosthetic Devices Revised
12/29/2021 *CG-SURG-78 Locoregional and Surgical Techniques for Treating Primary and Metastatic Liver Malignancies Revised

Note: AIM Speciality Health is an independent company providing some utilization review services for Healthy Blue + Medicare providers on behalf of Blue Cross and Blue Shield of North Carolina.

https://www.bluecrossnc.com/providers/blue-medicare-providers/healthy-blue-medicare

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross and
Blue Shield of North Carolina (Blue Cross NC) is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the property of their respective owners.
BNCCARE-0258-22 February 2022